Official Title
Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
Brief Title
Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
Protocol ID
NCT03938012
Lead Sponsor
National University Hospital, Singapore
Brief Summary
This study focuses on advanced lung and head and neck SCC tumours, with adjacent normal
lung tissues. Biopsies will be performed in National University Health System, Singapore
(NUHS) as part of participants' standard care. Patient blood was also required for
extraction of cell free DNA (cfDNA) and genomic DNA (gDNA). Patients' medical records
will also be reviewed for the purpose of this study.
Detailed Description
Primary objective:
To investigate the prevalence of MET and TP53 mutations, as well as HER2 and MET
amplification, in lung and head and neck tumours, through prospective collection of
tumour specimens in newly recruited patients.
Secondary objectives:
1. To distinguish the presence of somatic/germline MET and TP53 mutation in lung and
head and neck tumours.
2. To detect for amplifications of MET and/or HER2 genes in SCC samples.
3. To investigate the association and interaction of cMet and HER2 in SCC tumours.
4. To establish a prospective documation of clinical, histopathological, treatment and
follow-up (clinic pathological) data of newly recruited patients.
Study Period
Enrollment Count
80 participants
Eligibility Criteria
Inclusion Criteria:
1. Age 18 years or older
2. Histologic or cytologic confirmation of metastatic squamous cell carcinoma of the
lung or head and neck region
3. No other active malignancy within the past 24 months
4. Refractory disease
Exclusion Criteria:
1. Patient with other active malignancy within the past 24 months
2. Unable or unwilling to provide signed informed consent
Filters
Squamous Cell Carcinoma of the Lung
Squamous Cell Carcinoma of the Head and Neck
UNKNOWN
ADULT
OLDER_ADULT